Egl Nine Homolog 3 (C. Elegans) (EGLN3) antibody

Antigen: Egl Nine Homolog 3 (C. Elegans) (EGLN3)

Synonyms: PHD3, HIFPH3, FLJ21620, MGC125998, MGC125999, Phd3, SM-20, AI505553, AI648162, 2610021G09Rik, zgc:77019, wu:fj78a08, EGLN3, PHD-3

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB)

Catalog no.: ABIN151073

Additional Information

Alternative name: EGLN3 / PHD3

Gene ID: 112399, 112407, 54702

NCBI Acession: NP_0713561

Immunogen: The epitope recognized by this antibody maps to a region between residue 50 and 100of human Prolyl Hydroxylase Domain-Containing Protein 3 using the numbering given inentry NP_071356.1 (GeneID 112399).

Cross-Reactivity: Human

Description: HIF prolyl hydroxylase 3 is a prolyl hydroxylase that modifies HIF-alpha. Classic prolylhydroxylases are found in the endoplasmic reticulum and modify collagen, whereas HIFis an intracellular protein and the HPH sites do not resemble those modifying collagen. HIF is a transcriptional complex that plays a critical role in oxygen homeostasis. HPH isan essential component of the pathway through which cells sense oxygen. In thepresence of oxygen, HPHs convert specific prolyl residues in HIF-alpha tohydroxyproline, leading to HIF-alpha destruction. Low oxygen levels, sensed at thecellular level, cause the HIF conversion to be reduced so that HIF is stable and there isincreased angiogenesis.HPH-1, specifically, catalyzes the posttranslational formation of 4-hydroxyproline in HIFalpha proteins. It hydroxylates HIF-1 alpha at Pro(564) and HIF-2 alpha. It targets HIFthrough the hydroxylation for proteasomal degradation via the von Hippel-Lindau ubiquitylation complex. It may also play a role in cell growth regulation in muscle cellsand in apoptosis in neuronal tissues, promoting cell death through a caspase-dependentmechanism. Alternate Names: anti-EGL9 homolog of C. elegans 3 antibody, anti-EGLN3 antibody, anti-Factorresponsive smooth muscle protein antibody, anti-HIF Prolyl Hydroxylase 3 antibody,anti-HIFP4H3 antibody, anti-HIFPH3 antibody, anti-P4H3 antibody, anti-ProlylHydroxylase Domain Containing Protein 3 antibody, anti-SM20 antibody, anti-EGLN3antibody, anti-PHD3 antibody.

Specificity: This antibody is specific for HIF prolyl hydroxylase 3. Species Reactivity: Human and Rat. Does not appear to work in Mouse.

Application Details

Application Notes: This antibody may be used for Western blotting where a band is seen at ~27 kDa,representing HIF prolyl hydroxylase 3. This antibody has been tested in 293 cell lysates.Suggested working dilutions: *Western Blot 1:1,000-1:5000, Immunohistochemistry ND for this lotImmunoprecipitation ND for this lot

Concentration: 1 mg/ml

Purification: Aff - Purified

Buffer: Tris-citrate/phosphate buffer, pH 7 to 8. Preservative: 0.1% Sodium Azide.

Storage: Store at 4C. Do not freeze.

Restrictions: For Research Use only

Images

Detection of Human and Rat PHD3 by Western Blot. Samples: A. Lysate from cells that were transiently transfected with PHD1, PHD2, PHD3 or PHD4 constructs or in vitro translated PHD1, PHD2, PHD3, PHD4. B. Lysate from rat cells before or 9 hours after inducing hypoxia. Antibody: Affinity purified rabbit anti-PHD3 (ABIN151073) use at 1:1,000 (A) or 1:5,000 (B). Detection:Chemiluminence.

Publications

Bruick, McKnight: "A conserved family of prolyl-4-hydroxylases that modify HIF." in: Science (New York, N.Y.), Vol. 294, Issue 5545, pp. 1337-40, 2001 (PubMed).

Ivan, Haberberger, Gervasi et al.: "Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 21, pp. 13459-64, 2002 (PubMed).

Asikainen, Schneider, Waleh et al.: "Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 29, pp. 10212-7, 2005 (PubMed).

Jokilehto, Rantanen, Luukkaa et al.: "Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 4, pp. 1080-7, 2006 (PubMed).

Asikainen, Waleh, Schneider et al.: "Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo." in: American journal of physiology. Lung cellular and molecular physiology, Vol. 291, Issue 4, pp. L588-95, 2006 (PubMed).

Li, Yi, Sundy et al.: "Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys." in: American journal of physiology. Renal physiology, Vol. 292, Issue 1, pp. F207-16, 2007 (PubMed).

Fu, Menzies, Freeman et al.: "EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability." in: The Journal of biological chemistry, Vol. 282, Issue 17, pp. 12410-8, 2007 (PubMed).

Bai, Zeng, Hu et al.: "Expression and characteristic of synthetic human epidermal growth factor (hEGF) in transgenic tobacco plants." in: Biotechnology letters, Vol. 29, Issue 12, pp. 2007-12, 2007 (PubMed).

Rantanen, Pursiheimo, Hoegel et al.: "Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation." in: Molecular biology of the cell, Vol. 19, Issue 5, pp. 2231-40, 2008 (PubMed).

Ginouvès, Ilc, Macías et al.: "PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, Issue 12, pp. 4745-50, 2008 (PubMed).